&w=3840&q=100)
Apollo AyurVAID aims for 1,000 beds by 2028, eyes ₹500 crore turnover
Sohini Das Mumbai
Listen to This Article
Apollo AyurVAID, one of the largest Ayurvedic hospital chains in India, aims to have 1,000 beds across the country by 2028, as it sees demand for Ayurvedic treatment rising.
The chain, which currently operates 12 hospitals and had 185 beds in operation by the end of FY25, handles around 40,000-42,000 patients annually. It is targeting 200,000 patients annually in the next five years, by which time the hospital chain aims to reach a ₹500 crore turnover.
Speaking to Business Standard, Rajiv Vasudevan, Founder, CEO, and MD of Apollo AyurVAID, said that the company is expanding in cities like Chennai, Hyderabad,
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
44 minutes ago
- Business Standard
Indegene launches NEXT Medical Writing Automation
Indegene has announced the launch of NEXT Medical Writing Automation to accelerate the creation of high-quality documents across clinical development, regulatory submissions, and beyond. NEXT Medical Writing Automation, an advanced platform that combines deep medical writing expertise with generative AI (GenAI). Purpose-built by experienced medical writers, NEXT Medical Writing Automation operates within familiar environments like Microsoft Word, auto-generating compliant drafts that adapt to diverse sponsor formats and workflows. It integrates seamlessly with Regulatory Information Management (RIM) systems, maintaining traceability and consistency across documents. NEXT Medical Writing Automation combines Indegenes decades of domain knowledge with the power of its AI engine, Cortex. Sameer Lal, SVP, Enterprise Medical Solutions, Indegene, said, With automated scheduling, intelligent task assignments, and robust data flow integration, NEXT Medical Writing Automation helps life sciences organizations scale operations efficiently while maintaining a strong compliance backbone. As document requirements grow and scrutiny intensifies, such solutions become essential to sustaining operational excellence. We see this platform as more than automationits about elevating the entire practice of medical writing. Writers can now focus on strategic tasks and critical thinking, while the platform manages the heavy lift of data and formatting. Indegene is a digital-first life sciences commercialization company that partners with biopharmaceutical, emerging biotech, and medical device companies to develop products, bring them to market, and enhance their impact throughout the product lifecyclemore effectively, efficiently, and in a modern, technology-driven manner. The companys consolidated net profit jumped 24.1% to Rs 117.60 crore on 12.3% increase in net sales to Rs 755.60 crore in Q4 FY25 over Q4 FY24. The scrip declined 1.02% to settle at Rs 564.35 on the BSE.
Time of India
3 hours ago
- Time of India
WHO unveils roadmap for AI use in traditional medicine
New Delhi: Accepting India's proposal in this regard, the World Health Organisation (WHO) has prepared the first-ever roadmap for use of Artificial Intelligence in traditional medicine. The document titled 'Mapping the application of AI in traditional medicine ' was released on Friday. It mentions several initiatives taken by India to utilise AI and other digital tools for promotion of traditional systems of medicine. These include creation of the Traditional Knowledge Digital Library (TKDL) to digitise text-based formulations of Ayurveda, Unani, Siddha, Sowa Rigpa and practices of Yoga and a project called Ayurgenomics that aims to blend Ayurvedic principles with modern genomics. Ayush secretary Rajesh Kotecha said India had proposed the formation of an AI-in-Traditional-Medicine in the Global Initiative in AI for Health (GI-AI4H), which was accepted by partner nations. "Now, we are actively working with international bodies to set global AI standards for traditional medicine," he said. The WHO technical brief provides a forward-looking roadmap for AI-enabled research, diagnostics and personalised treatment pathways in traditional medicine sector. Kotecha said that based on this roadmap, the ministry of Ayush is developing indigenous AI chatbots to support practitioners and patients, thereby accelerating the modernisation and global reach of traditional medicine. "The Ayush Grid is deploying AI-powered tools - predictive systems and yoga recommendation - for personalised and citizen-centric healthcare," he said. Union minister of state (IC), Ayush ministry, Prataprao Jadhav said the recognition of India's AI-driven initiatives in the WHO's technical brief is a testament to the dedication of the country's scientists to advancing traditional medicine by integrating it with the latest technology. "Through the integration of AI with Ayush systems, India is not only preserving its rich medical heritage but also setting new benchmarks in personalised and evidence-based healthcare for the world," Jadhav said. One of the standout features of the WHO brief is the mention of Ayurgenomics, a scientific breakthrough that combines genomics with Ayurvedic principles. This initiative aims to identify predictive disease markers and personalise health recommendations by using AI-based analysis of Ayurvedic constitution types. The document also highlights efforts to decode the genomic and molecular basis of herbal formulations for repurposing in modern disease conditions-a major leap in integrating traditional wisdom with contemporary science. India's initiatives to digitise traditional knowledge are being praised as global models for the preservation and responsible use of indigenous medical heritage.
News18
5 hours ago
- News18
'Pulp Fiction? Not Quite': How Indian Oranges Are Powering A French Medicine To Treat Varicose Veins
'We are proud that the oranges grown in Indian soil are now an integral part of a medicine used by millions across the world," Aurelien Breton, managing director, Servier India, told News18. 'We procure oranges from Maharashtra, Telangana, Andhra Pradesh, MP, and Rajasthan currently." According to IQVIA data, Daflon's 500mg and 1000mg stand at a value of Rs 61 crore as per moving annual turnover, May 2025, ranking 2nd in the varicose therapy market. The average number of patients treated in a month is 1.2 lakhs. The citrus supply chain The Indian-sourced oranges are first processed locally—cleaned, dried, and converted into powder form. This citrus powder is then exported to Servier's manufacturing headquarters in France, where it undergoes sophisticated processing to extract the active pharmaceutical ingredients (APIs). Interestingly, those APIs are then re-imported back to India, where the final formulation of Daflon is completed for domestic distribution. This circular, transcontinental journey of a single orange—from a farm in Nagpur to a lab in northern France and back to a pharmacy shelf in Delhi—highlights the globalisation of pharmaceutical supply chains and India's growing importance as a trusted sourcing and manufacturing hub. The move wasn't just about logistics or cost-efficiency. According to Breton, Indian oranges matched the quality standards required for flavonoid extraction. 'We achieved 100% reliance on local Indian oranges through our Indian supply chain with effect from the financial year 2021." Indian oranges matched the former Spanish and Mexican counterparts. '2000 metric tons of small oranges were procured in the financial year 2023-24. We work with aggregators and farmers in multiple states in India," said Breton. Company set to bring precision cancer medicine Servier Pharma is set to bring precision cancer treatments to India. 'Unlike traditional chemotherapy, these therapies act on specific genetic mutations that are responsible for causing the cancer," Breton said. Out of three novel drugs coming into the Indian market, the first drug, Ivosidenib, targets a mutated protein known as isocitrate dehydrogenase 1 (IDH1), which is found in a subset of patients with cholangiocarcinoma (a type of biliary tract cancer) and acute myeloid leukemia (a form of blood cancer). 'Epidemiological data show a high prevalence of biliary tract cancers along the Ganga River basin, supporting the need for this targeted option, which can significantly delay disease progression. In clinical trials, Ivosidenib has demonstrated more than a threefold improvement in survival for AML (blood cancer) patients." The drug was officially launched in India in June 2025.
